Insulin-independent glucose uptake in skeletal muscle by coupled SGLT and Na,K-ATPase transport

This study identifies a novel, insulin-independent glucose uptake pathway in skeletal muscle called mSGLT, which is coupled to Na,K-ATPase activity and functions alongside GLUT4 to offer a potential therapeutic target for treating hyperglycemia when insulin sensitivity is impaired.

The Gist

The Big Picture: A New Door in the Muscle Wall

Imagine your body is a massive city, and glucose (sugar) is the fuel trucks trying to deliver energy to the neighborhoods (your muscles).

Usually, when you eat a meal, your body releases insulin. Think of insulin as a security guard with a master key. It walks up to the muscle cells, unlocks a specific door called GLUT4, and lets the fuel trucks in. This is how your body handles sugar after a big meal.

But what happens when you are running a marathon or lifting heavy weights? Your muscles need fuel right now, and they can't wait for the security guard (insulin) to show up. In fact, during intense exercise, your body actually shuts down the security guard system to save energy for the fight-or-flight response.

For decades, scientists knew muscles could still grab fuel during exercise without insulin, but they didn't know how. They thought the "GLUT4" door just opened a different way.

This paper discovers a completely new door.

The researchers found a hidden, emergency entrance in the muscle wall that works independently of the security guard. They call this new door "mSGLT."

---

How the New Door Works: The "Pump and Slide" Mechanism

To understand the difference between the old door (GLUT4) and the new door (mSGLT), let's look at how they let fuel in:

1. The Old Door (GLUT4): This is like a revolving door. It only opens when the security guard (insulin) gives the signal. Once open, the fuel trucks just roll in because there are more trucks outside than inside. It's passive and easy.
2. The New Door (mSGLT): This is like a conveyor belt powered by a battery.
   • Inside the muscle, there is a powerful pump (called Na,K-ATPase) that acts like a battery charger. It uses energy to create a strong suction force.
   • When you exercise, this pump goes into overdrive.
   • The new door (mSGLT) is attached to this pump. When the pump creates suction, it literally pulls the fuel trucks (glucose) inside, dragging them along with sodium ions.

The Analogy:
Imagine trying to get into a crowded club.

• GLUT4 is the VIP list. You need a specific name (insulin) to get in.
• mSGLT is the fire exit that opens when the fire alarm (exercise) goes off. It doesn't care about the VIP list; it just uses the pressure of the crowd to push people inside.

The "Magic" Discovery

The researchers proved this new door exists by using some clever tricks:

• The "Fake Sugar" Test: They used a type of sugar called αMDG. The old door (GLUT4) ignores this sugar completely, but the new door (mSGLT) loves it. They saw that when muscles were exercising, they were happily eating this "fake sugar," proving a new door was open.
• The "Pump Breaker" Test: They used a drug called ouabain to temporarily disable the battery pump (Na,K-ATPase). When the pump stopped, the new door (mSGLT) slammed shut, and the muscles stopped taking in the fake sugar. This proved the new door needs the pump to work.
• The "Insulin Blindness" Test: They tried to use insulin to open the new door. Nothing happened. The new door doesn't care about insulin at all.

Why This Matters: A Backup Plan for Diabetics

This discovery is a big deal for people with diabetes.

In diabetes, the "security guard" (insulin) is broken or ignored. The main door (GLUT4) is jammed. Usually, this means sugar stays in the blood, causing high blood sugar levels.

However, this paper shows that exercise still works for diabetics. Even if the insulin door is broken, the "fire exit" (mSGLT) is still fully functional. When a diabetic person exercises, their muscles can still suck up sugar using this new pump-driven door.

The Takeaway:

• Exercise is medicine: It works even when insulin fails because it uses a different, insulin-independent pathway.
• A New Target: Scientists can now look for drugs that specifically boost this "mSGLT" door. This could lead to new treatments that help lower blood sugar in diabetics without needing to fix the broken insulin system.

Summary in One Sentence

Scientists found a hidden "emergency fuel door" in our muscles that works by using a suction pump during exercise, allowing us to burn sugar even when our insulin system is broken.

Technical Summary

1. Problem Statement

Skeletal muscle is the primary site for glucose disposal and homeostasis. While insulin-stimulated glucose uptake (mediated by GLUT4 translocation) is well-characterized, the mechanisms underlying insulin-independent glucose uptake remain incompletely understood. This pathway is critical during exercise, stress, and in metabolic disorders like diabetes and obesity, where it can account for up to 70% of total glucose disposal.

• The Gap: Existing models suggest non-insulin uptake relies on alternative GLUT4 translocation mechanisms. However, GLUT4 knockout models show variable phenotypes, and known GLUT transporters (GLUT1, 3, 4, 6, 10) do not fully explain the capacity for glucose uptake under conditions where insulin signaling is impaired or absent.
• The Hypothesis: The authors hypothesized that a Sodium-Glucose Linked Transporter (SGLT), which utilizes the Na+ gradient generated by Na,K-ATPase, contributes to insulin-independent glucose uptake in skeletal muscle.

2. Methodology

The study utilized isolated mouse Extensor Digitorum Longus (EDL) muscles under nominally insulin-free conditions (achieved via fasting, isolation from circulation, and insulin-free buffers).

• Simultaneous Uptake Measurement (ICP-MS): A novel application of Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) was used to measure the simultaneous uptake of:
  • Rubidium (Rb): A congener for K+, used as a tracer for Na,K-ATPase activity.
  • 13C-labeled Hexoses: To distinguish between transporter types:
    • 6-13C-Glucose: Substrate for all transporters.
    • 6-13C-2-deoxy-D-glucose (2-DG): Specific substrate for GLUTs (not SGLTs).
    • 6-13C-α-methyl-D-glucoside (αMDG): Specific substrate for SGLTs (not GLUT4).
• Stimulation Protocols: Muscles were tested at rest, during electrical tetanic contraction, and under adrenergic stimulation (salbutamol).
• Pharmacological Modulation:
  • Ouabain (0.75 µM): To specifically inhibit the Na,K-ATPase-α2 isoform (the dominant isoform in rodent muscle).
  • Insulin (100 nM): To stimulate GLUT4.
  • SGLT Inhibitors: Phlorizin and Empagliflozin to test affinity for the putative muscle transporter.
• Molecular Characterization:
  • RT-qPCR & PCR: To detect Slc5a2 (SGLT2) transcripts in muscle vs. kidney.
  • Immunohistochemistry (IHC): To localize SGLT2, Na,K-ATPase-α2, and MAP17 (SGLT2 regulatory subunit) in muscle t-tubules.
  • Western Blotting: To detect protein expression and size, using two independent SGLT2-specific antibodies under different denaturing conditions.

3. Key Contributions

• Discovery of "mSGLT": Identification of a previously unrecognized, insulin-independent glucose uptake pathway in skeletal muscle termed mSGLT.
• Mechanistic Coupling: Demonstration that this pathway is functionally coupled to Na,K-ATPase-α2 activity, relying on the inward Na+ gradient rather than facilitated diffusion.
• Additivity: Proof that mSGLT and GLUT4 operate as independent, additive pathways for glucose disposal.
• Molecular Paradox: Resolution of the discrepancy between the presence of SGLT2-like proteins in muscle and the absence of full-length Slc5a2 transcripts, suggesting a post-transcriptional or post-translational variant.

4. Key Results

A. Functional Evidence of mSGLT

• Contraction & Na,K-ATPase: Muscle contraction dramatically increased uptake of both Rb (Na,K-ATPase activity) and αMDG.
• Ouabain Sensitivity: Inhibition of Na,K-ATPase-α2 with ouabain reduced Rb uptake by ~92% and αMDG uptake by ~98%. Crucially, ouabain did not inhibit insulin-stimulated 2-DG uptake (GLUT4), confirming the distinct mechanism.
• Adrenergic Stimulation: Salbutamol (a β2-agonist) stimulated Na,K-ATPase and induced a parallel increase in αMDG uptake (2.74-fold), confirming that Na,K-ATPase stimulation alone is sufficient to drive mSGLT.
• Additivity: During contraction, both 2-DG (GLUT4) and αMDG (mSGLT) were transported simultaneously. αMDG uptake accounted for ~13–16% of total hexose uptake during contraction.

B. Molecular Identity and Localization

• Transcript Analysis: While short sequences of Slc5a2 were detected in muscle via RT-qPCR, no full-length Slc5a2 transcript was found in muscle (unlike in the kidney). This suggests mSGLT is not the canonical kidney SGLT2.
• Protein Detection: Two independent SGLT2-specific antibodies recognized a protein in muscle lysates:
  • A ~50 kDa band (under standard denaturation).
  • A ~72 kDa band (under aggressive denaturation with DTT), matching the size of full-length kidney SGLT2.
• Localization: Immunohistochemistry showed co-localization of the SGLT2 signal, Na,K-ATPase-α2, and MAP17 specifically in the t-tubule membranes of both fast and slow muscle fibers.
• Pharmacology: Standard SGLT2 inhibitors (Empagliflozin) and SGLT1 inhibitors (Phlorizin) showed weak or no affinity for mSGLT. Empagliflozin (500 nM) only inhibited mSGLT by ~25%, whereas it inhibits kidney SGLT2 with an IC50 of 3 nM.

5. Significance and Implications

• Physiological Mechanism: The study proposes a model where muscle contraction or adrenergic stress activates Na,K-ATPase-α2 in the t-tubules. This creates a local Na+ gradient that drives mSGLT to import glucose (and Na+) independently of insulin. This provides a robust mechanism for glucose disposal when insulin signaling is compromised (e.g., in Type 2 Diabetes).
• Therapeutic Potential: mSGLT represents a muscle-specific therapeutic target. Since it is insulin-independent, activating or modulating this pathway could lower blood glucose in diabetic patients who are resistant to insulin.
• Molecular Mystery: The existence of a functional SGLT-like protein without a full-length transcript suggests a novel biological mechanism, possibly involving a truncated transcript variant, a splice variant, or a post-translational modification of a related gene family member.
• Methodological Advance: The use of ICP-MS to simultaneously track inorganic ions (Rb) and organic substrates (13C-hexoses) provides a powerful new tool for dissecting coupled transport mechanisms in intact tissues.

In conclusion, the paper defines a new, insulin-independent glucose uptake pathway in skeletal muscle driven by the Na,K-ATPase-α2 gradient, offering a potential explanation for glucose disposal in diabetes and a new avenue for therapeutic intervention.